The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Does Sourcing Strategy Matter? Executives Debate the Influence of Outsourcing Model on Clinical Trial Execution
Mitchell A. Katz, PhD
Head of Clinical Research and Drug Safety Operations
Purdue Pharma L.P., United States
In this provocative session, executives from various sponsor organizations will react to the 2017 industry report on risk in clinical trials. They will share its 2017 industry findings on the state of clinical outsourcing, risk assessment, and risk-based approaches to managing quality and oversight in the context of a changing regulatory landscape. With a near equal balance of respondents identifying as using primarily FSP or primarily Full-Service models, they will shed light on what the data says about the impact of sourcing model on quality, relationships, and risk-based approaches.Forward-thinking executive leaders from pharma and CRO respondents will respond to the findings with their own interpretations, describe strategies where threats and opportunities may be addressed, and promote their own unique view.
Learning Objective : Assess the impact of clinical outsourcing model on quality, relationships, and risk-based approaches; Describe strategies addressing threats and opportunities in the changing regulatory landscape.
David M. Johnston, PhD
Executive Vice President, Clinical Development
PPD , United States
Senior Vice President, Head of Global Clinical Operations
EMD Serono, Inc., United States
Jeremy G. Chadwick, PhD, MSc
Group Vice President, Clinical Development Operations
Shire, United States